Micellar nanomedicine of human neuropeptide Y

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 4, 2011, Pages 464-471

  Kuzmis, Antonina ^a   Lim, Sok Bee ^a   Desai, Esha ^a   Jeon, Eunjung ^a   Lee, Bao Shiang ^a   Rubinstein, Israel ^a,c   Önyüksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

CAMP; Dipeptydyl peptidase 4; Human neuropeptide Y (NPY) medicine; Stability; Sterically stabilized micelles (SSM)

Indexed keywords

CAMP; DIPEPTYDYL PEPTIDASE-4; DISEASE STATE; ENZYMATIC DEGRADATION; FURTHER DEVELOPMENT; HELIX CONFORMATION; IN-VITRO; NEUROPEPTIDE Y; PHYSIOLOGICAL FUNCTIONS; SELF-ASSOCIATIONS; STERICALLY STABILIZED MICELLES (SSM);

ACTIVATION ANALYSIS; CONFORMATIONS; DEGRADATION; FETAL MONITORING; MEDICAL NANOTECHNOLOGY; MICELLES; PEPTIDES; PHOSPHOLIPIDS;

ASSOCIATION REACTIONS;

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; MONOMER; NEUROPEPTIDE Y; PHOSPHOLIPID;

ALPHA HELIX; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; MOLECULAR WEIGHT; NANOMEDICINE; NEUROEPITHELIOMA; PARTICLE SIZE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL;

CYCLIC AMP; DIPEPTIDYL PEPTIDASE 4; DRUG STABILITY; HUMANS; MICELLES; NANOMEDICINE; NEUROPEPTIDE Y; PHOSPHOLIPIDS;

EID: 79960703248     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.01.004     Document Type: Article

References (50)

1. Eaton K., Sallee F.R., Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem 2007, 7:1645-1659.
2. Harro J. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids 2006, 31:215-230.
3. Laviano A., Inui A., Meguid M.M., Molfino A., Conte C., Rossi Fanelli F. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition 2008, 24:802-805.
4. Morley J.E., Farr S.A. Cachexia and neuropeptide Y. Nutrition 2008, 24:815-819.
5. Benarroch E.E., Neuropeptide Y. Its multiple effects in the CNS and potential clinical significance. Neurology 2009, 72:1016-1020.
6. Zhang L., Macia L., Turner N., Enriquez R.F., Riepler S.J., Nguyen A.D., et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2010, 34:357-373.
7. Lee N.J., Herzog H. NPY regulation of bone remodelling. Neuropeptides 2009, 43:457-463.
8. Moriya R., Shirakura T., Hirose H., Kanno T., Suzuki J., Kanatani A. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Peptides 2010, 31:671-675.
9. Prod'homme T., Weber M.S., Steinman L., Zamvil S.S. A neuropeptide in immune-mediated inflammation, Y?. Trends Immunol 2006, 27:164-167.
10. Korner M., Reubi J.C. NPY receptors in human cancer: a review of current knowledge. Peptides 2007, 28:419-425.
11. Bader R., Zerbe O. Are hormones from the neuropeptide Y family recognized by their receptors from the membrane-bound state?. Chembiochem 2005, 6:1520-1534.
12. Berglund M.M., Hipskind P.A., Gehlert D.R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 2003, 228:217-244.
13. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
14. Baldock P.A., Lee N.J., Driessler F., Lin S., Allison S., Stehrer B., et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 2009, 4:e8415.
15. Reubi J.C., Gugger M., Waser B., Schaer J.C. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001, 61:4636-4641.
16. Kitlinska J., Abe K., Kuo L., Pons J., Yu M., Li L., et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005, 65:1719-1728.
17. Ruscica M., Dozio E., Motta M., Magni P. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 2007, 28:426-434.
18. Abid K., Rochat B., Lassahn P.G., Stocklin R., Michalet S., Brakch N., et al. Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein. J Biol Chem 2009, 284:24715-24724.
19. Sun L.S., Du F., Schechter W.S., Quaegebeur J.M., Vulliemoz Y. Plasma neuropeptide Y and catecholamines in pediatric patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1997, 113:278-284.
20. Bader R., Bettio A., Beck-Sickinger A.G., Zerbe O. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection. J Mol Biol 2001, 305:307-329.
21. Dyck M., Losche M. Interaction of the neurotransmitter, neuropeptide Y, with phospholipid membranes: film balance and fluorescence microscopy studies. J Phys Chem B 2006, 110:22143-22151.
22. Frerker N., Wagner L., Wolf R., Heiser U., Hoffmann T., Rahfeld J.U., et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 2007, 28:257-268.
23. Lim S.B., Rubinstein I., Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm 2008, 356:345-350.
24. Onyuksel H., Ikezaki H., Patel M., Gao X.P., Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 1999, 16:155-160.
25. Lim S.B., Rubinstein I., Sadikot R.T., Artwohl J.E., Onyuksel H. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res; 2010, in press.
26. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci 2004, 93:2476-2487.
27. Sethi V., Onyuksel H., Rubinstein I. Enhanced circulation half-life and reduced clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized micelles (SSM) in mice with collagen-induced arthritis (CIA). AAPS Pharm Sci 2003, 5:M1045.
28. Rubinstein I., Patel M., Ikezaki H., Dagar S., Onyuksel H. Conformation and vasoreactivity of VIP in phospholipids: Effects of calmodulin. Peptides 1999, 20:1497-1501.
29. Gololobov G., Noda Y., Sherman S., Rubinstein I., Baranowska-Kortylewicz J., Paul S. Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther 1998, 285:753-758.
30. Arleth L., Ashok B., Onyuksel H., Thiyagarajan P., Jacob J., Hjelm R.P. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 2005, 21:3279-3290.
31. Lim Y., Lee M. Nanostructures of β-sheet peptides: Steps towards bioactive functional materials. J Mater Chem 2008, 18:723-727.
32. Mentlein R., Dahms P., Grandt D., Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993, 49:133-144.
33. Lee B.S., Krishnanchettiar S., Lateef S.S., Gupta S. Analyses of the in vitro non-enzymatic glycation of peptides/proteins by matrix-assisted laser desorption/ionization mass spectrometry. Int J Mass Spectrometry 2007, 260:67-74.
34. Lee B.S., Krishnanchettiar S., Lateef S.S., Gupta S. Characterization of oligosaccharide moieties of glycopeptides by microwave-assisted partial acid hydrolysis and mass spectrometry. Rapid Commun Mass Spectrom 2005, 19:1545-1550.
35. Sheriff S., F Qureshy A., T Chance W., Kasckow J.W., Balasubramaniam A. Predominant role by CaM kinase in NPY Y(1) receptor signaling: involvement of CREB [corrected]. Peptides 2002, 23:87-96.
36. Zhang H., Pandey S.C. Effects of PKA modulation on the expression of neuropeptide Y in rat amygdaloid structures during ethanol withdrawal. Peptides 2003, 24:1397-1402.
37. Gordon E.A., Kohout T.A., Fishman P.H. Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line. J Neurochem 1990, 55:506-513.
38. Nordmann A., Blommers M.J., Fretz H., Arvinte T., Drake A.F. Aspects of the molecular structure and dynamics of neuropeptide Y. Eur J Biochem 1999, 261:216-226.
39. Thiele T.E., Badia-Elder N.E. A role for neuropeptide Y in alcohol intake control: evidence from human and animal research. Physiol Behav 2003, 79:95-101.
40. Jung S.J., Chang J.W., Won R., Cha M.H., Nam T.S., Lee H.J., et al. Modulation of neuropathic pain by galanin and neuropeptide Y at the level of the medulla in rats. Int J Neurosci 2009, 119:1941-1955.
41. Bedoui S., Miyake S., Lin Y., Miyamoto K., Oki S., Kawamura N., et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 2003, 171:3451-3458.
42. Khan I.U., Zwanziger D., Bohme I., Javed M., Naseer H., Hyder S.W., et al. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew Chem Int Ed Engl 2010, 49:1155-1158.
43. Bettio A., Beck-Sickinger A.G. Biophysical methods to study ligand-receptor interactions of neuropeptide Y. Biopolymers 2001, 60:420-437.
44. Lerch M., Mayrhofer M., Zerbe O. Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors. J Mol Biol 2004, 339:1153-1168.
45. Arscott W.T., LaBauve A.E., May V., Wesley U.V. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene 2009, 28:479-491.
46. Arumugam K., Subramanian G.S., Mallayasamy S.R., Averineni R.K., Reddy M.S., Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008, 58:287-297.
47. Shwe T.T.W., Mitsushima D., Yamamoto S., Fukushima A., Funabashi T., Kobayashi T., et al. Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure. Toxicol Appl Pharmacol 2008, 226:192-198.
48. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006, 27:3482-3490.
49. Intranasal administration of neuropeptide Y in healthy male volunteers (NPY); NCT00748956. Available from: Accessed January 20, 2010. http://clinicaltrials.gov/ct2/show/NCT00748956?term=npy&rank=1.
50. Krishnadas A., Onyuksel H., Rubinstein I. Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr Pharm Des 2003, 9:1005-1012.